Table 3.
Outcome indicators included in RCTs.
| Yang 2022 | Zhu 2021 | Kim 2021 | Zhou 2019 | Qiu 2012 | Chen 2011 | Chen2009 | ||
|---|---|---|---|---|---|---|---|---|
| Primary outcome | CPR (%) | RR 1.71, 95%CI, [0.59, 4.99], p>0.05 | RR 1.50, 95%CI, [0.61, 3.69], p>0.05 | |||||
| Second outcome | Fertilization rate (%) | RR 1.08, 95%CI, [0.96, 1.20], p>0.05 | RR 1.03, p>0.05 | RR 0.97, 95%CI, [0.71, 1.31], p>0.05 | MD 11.32, 95%CI, [0.59, 22.05], p<0.05* | RR 1.03, p>0.05 | RR 0.90, 95%CI, [0.77, 1.05], p>0.05 | RR 1.18, p<0.05* |
| Number of oocytes retrieved (n) | MD -0.42, 95%CI, [-1.11, 0.27], p>0.05 | MD 0.34, 95%CI, [-0.71, 1.39], p>0.05 | MD 1.45, 95%CI, [-0.08, 2.98], p>0.05 | MD 1.81, 95%CI, [0.60, 3.02], p<0.05* | MD 2.71, 95%CI, [2.12, 3.30], p<0.05* | MD 1.09, 95%CI, [0.27, 1.91], p<0.05* | MD 0.20, 95%CI, [-0.42, 0.82], p>0.05 | |
| High-quality embryos rate (%) | RR 0.98, 95%CI, [0.89, 1.07], p>0.05 | MD 17.65, 95%CI, [5.74, 29.56], p<0.01* | MD 18.99, 95%CI, [3.83, 34.15], p<0.05* | RR 1.06, p<0.05* | RR 0.89, 95%CI, [0.68, 1.17], p>0.05 | RR 1.41, p<0.05* | ||
| Implantation rate (%) | RR 1.91, 95%CI, [0.63, 5.79], p>0.05 | RR 2.28, 95%CI, [0.96, 5.44], p<0.05* | ||||||
| Thickness of endometrium (mm) | MD 0.20, 95%CI, [-0.40, 0.80], p>0.05 | MD 1.20, 95%CI, [0.40, 2.00], p<0.05* | MD 0.05, 95%CI, [-0.03, 0.13], p>0.05 | |||||
| Cycle cancellation rate (%) | MD 0.66, 95%CI, [0.24, 1.84], p>0.05 | RR 0.62, p>0.05 | RR 0.60, 95%CI, [0.11, 3.36], p>0.05 | RR 0.67, 95%CI, [0.12, 3.71], p>0.05 | ||||
| Index for reproductive endocrinology | FSH (IU/L) | MD -0.96, 95%CI, [-2.81, 0.89], p>0.05 | MD -1.79, 95%CI, [-3.36, -0.22], p<0.05* | MD -1.05, 95%CI, [-3.00, 0.90], p<0.05* | MD -1.79, 95%CI, [-3.36, -0.22] | |||
| LH (IU/L) | p>0.05 | MD -0.54, 95%CI, [-2.23, 1.15], p>0.05 | MD 0.00, 95%CI, [-0.84, 0.84], p>0.05 | MD -0.86, 95%CI, [-2.43, 0.71], p>0.05 | MD 0.13, 95%CI, [-0.19, 0.45], p>0.05 | |||
| E2 (pmol/L) | MD 1678.71, 95%CI, [1588.40, 1769.02], p<0.05* | MD 2176.74, 95%CI, [190.66, 4162.82], p<0.05* | MD 915.53, 95%CI, [199.50, 1631.56], p<0.05* | |||||
| AFC (n) | MD -0.47, 95%CI, [-2.44, 1.50], p>0.05 | MD 1.76, 95%CI, [1.23, 2.29], p<0.05* | MD 1.08, 95%CI, [0.10, 2.06], p>0.05 | |||||
| AMH (ng/mL) | MD 0.08, 95%CI, [-0.29, 0.45], p>0.05 | |||||||
| Dose of Gn (IU) | MD -24.78, 95%CI, [-191.42, 141.86], p>0.05 | MD -20.37, 95%CI, [-434.37, 393.63], p>0.05 | MD 11.55, 95%CI, [-396.11, 419.21], p>0.05 | |||||
| Duration of Gn (day) | MD 0.61, 95%CI, [-0.04, 1.26], p>0.05 | MD -0.03, 95%CI, [-1.35, 1.29], p>0.05 | MD 0.44, 95%CI, [-0.36, 1.24], p>0.05 | |||||
| Adverse effect | Miscarriage rate (%) | RR 0.67, 95%CI, [0.20, 2.26], p>0.05 |
CPR, Clinical pregnancy rate; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estradiol; AMH, anti-mullerian hormone; AFC, antral follicle count; Gn, gonadotropin; MD, mean difference; CI, confidence Intervals; RR, risk ratio.